ALLIGATOR BIOSCIENCE NPV revenue for the last year amounted to 62.00 M SEK, the most of which — 58.11 M SEK — came from its highest performing source at the moment, Antibody-based Medicines, the year earlier bringing 35.70 M SEK. The greatest contribution to the revenue figure was made by Finland — last year it brought ALLIGATOR BIOSCIENCE NPV 58.11 M SEK, and the year before that — 35.70 M SEK.